Damora Therapeutics, Inc.
DMRA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001800315
In the last 90 days, Damora Therapeutics, Inc. insiders filed 1 open-market purchase and 1 sale; 104 institutions reported holding it in 13F filings for Q2 2026, worth $1.67B in total; Viking Global Investors is the only superinvestor holding it.
Q4 2021 vs. Q3 2021
How the institutions holding Damora Therapeutics, Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 25 | 26 | +1 |
| Shares | 10.4M | 10.1M | −341.4K (−3.3%) |
| Value | $37.2M | $30.5M | −$6.74M (−18.1%) |
New holders (5)
Institutions that held Damora Therapeutics, Inc. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Anson Funds Management LP | 183,530 | $556.0K | 0.08% |
| Susquehanna International Group, LLP | 15,964 | $48.0K | 0.00% |
| UBS Group AG | 6,743 | $20.0K | 0.00% |
| Simplex Trading, LLC | 554 | $1.00K | 0.00% |
| Morgan Stanley | 1 | $0 | 0.00% |
Sold out (4)
Institutions that held Damora Therapeutics, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Virtu Financial LLC | 24,587 | $88.0K |
| Tower Research Capital LLC (TRC) | 13,129 | $47.0K |
| Harbour Investments, Inc. | 300 | $1.00K |
| Advisor Group Holdings, Inc. | 400 | $1.00K |